421 related articles for article (PubMed ID: 33643443)
1. Current and future treatment options for
Hong L; Zhang J; Heymach JV; Le X
Ther Adv Med Oncol; 2021; 13():1758835921992976. PubMed ID: 33643443
[TBL] [Abstract][Full Text] [Related]
2. Lung Cancer with
Fujino T; Suda K; Mitsudomi T
Lung Cancer (Auckl); 2021; 12():35-50. PubMed ID: 34295201
[No Abstract] [Full Text] [Related]
3. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
4. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
6. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
7. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
Fraser M; Seetharamu N; Diamond M; Lee CS
Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971
[TBL] [Abstract][Full Text] [Related]
8. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
9. Detection of
Subramanian J; Tawfik O
Expert Rev Anticancer Ther; 2021 Aug; 21(8):877-886. PubMed ID: 33957836
[No Abstract] [Full Text] [Related]
10. Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
Tan AC; Loh TJ; Kwang XL; Tan GS; Lim KH; Tan DSW
Lung Cancer (Auckl); 2021; 12():11-20. PubMed ID: 33776501
[TBL] [Abstract][Full Text] [Related]
11. The Current Landscape for
Desai A; Cuellar S
J Adv Pract Oncol; 2022 Jul; 13(5):539-544. PubMed ID: 35910499
[TBL] [Abstract][Full Text] [Related]
12. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
13. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
14. MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Fernandes M; Hoggard B; Jamme P; Paget S; Truong MJ; Grégoire V; Vinchent A; Descarpentries C; Morabito A; Stanislovas J; Farage E; Meneboo JP; Sebda S; Bouchekioua-Bouzaghou K; Nollet M; Humez S; Perera T; Fromme P; Grumolato L; Figeac M; Copin MC; Tulasne D; Cortot AB; Kermorgant S; Kherrouche Z
Mol Oncol; 2023 Nov; 17(11):2257-2274. PubMed ID: 36799689
[TBL] [Abstract][Full Text] [Related]
15. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
[TBL] [Abstract][Full Text] [Related]
16. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Tepotinib as a Treatment Option in
Miyashita Y; Hirotsu Y; Nagakubo Y; Kobayashi H; Kawaguchi M; Hata K; Saito R; Kakizaki Y; Tsutsui T; Oyama T; Omata M
JTO Clin Res Rep; 2024 Jun; 5(6):100679. PubMed ID: 38841537
[TBL] [Abstract][Full Text] [Related]
18. A narrative review of MET inhibitors in non-small cell lung cancer with
Santarpia M; Massafra M; Gebbia V; D'Aquino A; Garipoli C; Altavilla G; Rosell R
Transl Lung Cancer Res; 2021 Mar; 10(3):1536-1556. PubMed ID: 33889528
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
Lee JK; Madison R; Classon A; Gjoerup O; Rosenzweig M; Frampton GM; Alexander BM; Oxnard GR; Venstrom JM; Awad MM; Schrock AB
JCO Precis Oncol; 2021; 5():. PubMed ID: 34476332
[TBL] [Abstract][Full Text] [Related]
20. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q; Shi X; Zhou X; Liang Z; Lu S; Wu Y
Ther Adv Med Oncol; 2024; 16():17588359231216096. PubMed ID: 38188466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
